Poisoning Due to Class IA Antiarrhythmic Drugs: Quinidine, Procainamide and Disopyramide

Drug Safety

Volumn 5, Issue 6, 1990, Pages 393-420

  Kim, Susan Y ^a   Benowitz, Neal L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACECAINIDE; ANTIARRHYTHMIC AGENT; CIMETIDINE; DISOPYRAMIDE; ERYTHROMYCIN; KETOCONAZOLE; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; QUINIDINE; TRIMETHOPRIM; VERAPAMIL;

ANTICHOLINERGIC EFFECT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INTOXICATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; NEUROTOXICITY; REVIEW;

ANIMAL; ANTI-ARRHYTHMIA AGENTS; DISOPYRAMIDE; HUMAN; POISONING; PROCAINAMIDE; QUINIDINE;

EID: 0025002043     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199005060-00002     Document Type: Review

References (197)

1. Pure red cell aplasia in procainamide induced systemic lupus erythematosus: report and review of the literature
2. Successful treatment by overdrive pacing of recurrent quinidine syncope due to ventricular tachycardia
3. Gastrointestinal dialysis of disopyramide in healthy subjects
4. Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies
5. Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations
6. Dose-ranging trial of N-acetylproeainamide in patients with premature ventricular contractions
7. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide
8. Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia
9. Cardiotoxic effects of quinidine and their treatment
10. Quinidine sulfate induced hypoplastic anemia and agranulocytosis
11. Torsade de pointes due to quinidine: observations in 31 patients
12. Long-term therapy with disopyramide phosphate: side effects and effectiveness
13. Leukocytosis and left shift associated with quinidine fever
14. Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate
15. Reversal of the cardiotoxic effects of quinidine by molar sodium lactate
16. The reversal of cardiotoxic effects of quinidine by molar sodium lactate: an experimental study
17. Quinide, procainamide and disopyramide
18. Cardiac disturbances in the toxicologic patient
19. The use of procainamide and lidocaine in the treatment of cardiac arrhythmias
20. Kinetics of disopyramide in decreased hepatic function
21. Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman
22. Hemoperfusion for treatment of N-acetylprocainamide intoxication
23. Granulomatous hepatitis as a manifestation of quinidine hypersensitivity
24. The effect of serum potassium concentration on quinidine toxicity
25. Disopyramide: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias
26. Effects of quinidine on ventricular repolarization
27. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability
28. Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias
29. Enhancement of procainamide-induced rate-dependent conduction slowing by elevated myocardial extracellular potassium concentration in vivo
30. Effect of quinidine on the ventricular complex of the electrocardiogram with special reference to the duration of the Q-T interval
31. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program
32. Two distinct quinidine-induced rheumatic syndromes
33. Clinical pharmacokinetics of N-acetylprocainamide
34. Pharmacokinetic studies of quinidine in patients with arrhythmias
35. Sodium lactate reversal of quinidine effect studied in rabbit atria by the microelectrode technique
36. Disopyramideinduced hypoglycaemia and increased serum insulin
37. Azarnoff DI. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide
38. Interaction of quinidine with anticonvulsant drugs
39. Electrophysiologic antagonism of quinidine and bretylium tosylate
40. Acute psychosis as idiosyncratic reaction to quinidine: report of two cases
41. Cardiovascular collapse associated with disopyramide therapy
42. Ventricular tachycardia-flutter associated with disopyramide therapy: a report of three cases
43. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration
44. Procainamide — a hazard in myasthenia gravis
45. Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function
46. Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome
47. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine
48. Quinidine-induced long QTU interval and torsade de pointes: role of bradycardia-dependent early afterdepolarizations
49. Antiarrhythmic potency of N-acetylprocainamide
50. Depression of the heart by quinidine and its treatment
51. Drug fever of quinidine
52. Septic complications of procainamide-induced agranulocytosis: report of two cases
53. The renal elimination of procainamide
54. Altered therapeutic range for quinidine after myocardial infarction and cardiac surgery
55. Pacemaker failure due to procainamide toxicity
56. Quinidine hypersensitivity and liver involvement: a survey of 32 patients
57. Quinidine excretion in aciduria and alkaluria
58. Effects of digoxin and quinidine on intracellular electrolytes of the rabbit heart
59. Pure red cell aplasia associated with administration of sustained-release procainamide
60. Elimination of procainamide in end stage renal failure
61. Acute intoxication with disopyramide: clinical and experimental study by hemoperfusion on Amberlite XAD 4 Resin
62. Prevention of the cardiotoxic effect of quinidine by isoproterenol
63. Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle
64. max in guinea pig ventricular myocardium
65. Sino-atrial block in man provoked by quinidine
66. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration
67. Hemoperfusion in quinidine intoxication
68. Skeletal muscle weakness resulting from quinidine ingestion
69. Clearance of quinidine during peritoneal dialysis
70. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance
71. Fatal overdosage with disopyramide
72. Experimental disopyramide poisoning: treatment by cardiovascular support and with charcoal hemoperfusion
73. The comparative inotropic effects of six clinically used antiarrhythmic agents
74. Effects of long-term treatment with procaine amide: a prospective study with special regard to ANF and SLE in fast and slow acetylators
75. Fever and chills as reaction to procainamide hydrochloride therapy
76. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans
77. Electrophysiology and pharmacology of cardiac arrhythmias: VII
78. Negative inotropic effect of class-1-antiarrhythmic drugs: comparison of flecainide with disopyramide and quinidine
79. Successful management of serious disopyramide poisoning
80. The contribution of Na channel block to the negative inotropic effect of antiarrhythmic drugs
81. Disopyramide dialysability
82. Severe neutropenia due to sustained-release procainamide
83. Fatal overdose of disopyramide in a child
84. Intoxications aigües par le disopyramide
85. Diaphragmatic paralysis
86. Haemodynamic effects of intravenous disopyramide in heart failure
87. Effects of intravenous N-acetylprocainamide on hemodynamics and left ventricular function in man
88. The electrophysiological effects of intramuscular quinidine on the atrioventricular conducting system in man
89. Effect of quinidine on plasma cholinesterase activity and succinylcholine neuromuscular blockade
90. Inhibitory effect of quinidine on plasma pseudocholinesterase activity in pregnant women
91. The effect of procainamide on plasma cholinesterase activity
92. Disopyramide pharmacokinetics and metabolism: effect of inducers
93. Quinidine syncope; report of a case successfully treated with lidocaine
94. Clinical pharmacokinetics of procainamide
95. Depressant effect of magnesium on early afterdepolarizations and triggered activity induced by cesium, quinidine and 4-aminopyridine in canine cardiac Purkinje fibers
96. Contribution of quinidine metabolites to electrophysiologic responses in human subjects
97. Quinidine overdose. Neurological and cardiovascular toxicity in a normal person
98. Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure
99. Dynamic variability of binding of antiarrhythmic drugs during the evolution of acute myocardial infarction
100. Quinidine elimination in patients with congestive heart failure or poor renal function
101. Fetal supraventricular tachycardia treated with high-dose quinidine: toxicity associated with marked elevation of the metabolite, 3(S)-3-hydroxyquinidine
102. Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome
103. Quinidine-induced hepatitis. A common and reversible hypersensitivity reaction
104. Quinidine hepatotoxicity. A report of a case and review of the literature
105. Pharmacokinetics of procainamide in man
106. Procainamide dosage schedules, plasma concentrations and clinical effects
107. Combined effect of disopyramide and bethanechol: use of bethanechol to prevent anticholinergic side effects of disopyramide without reduction of antiarrhythmic efficacy
108. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide
109. Long-term use of procaine amide following acute myocardial infarction
110. Quinidine-induced ventricular flutter and fibrillation without digitalis therapy
111. Dose dependent effect of cimetidine on procainamide disposition in man
112. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure
113. Effects of N-acetylprocainamide and procainamide on myocardial contractile force, heart rate, and blood pressure
114. Myopathy after short term administration of procainamide
115. Thrombosis associated with procainamide-induced lupus anticoagulant
116. Disopyramide-induced ventricular tachycardia
117. Approaches to sudden death from coronary heart disease
118. Agranulocytosis secondary to extendedrelease procainamide: a case report and review of the literature
119. Absorption kinetics of procainamide in humans
120. Hemodynamic effects of intravenously administered quinidine on the transplanted human heart
121. Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy
122. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity
123. Respiratory failure produced by severe procainamide intoxication in a patient with preexisting peripheral neuropathy caused by amiodarone
124. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy
125. Disopyramide
126. Idiosyncratic drug-induced thrombocytopenia
127. Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas
128. Severe hypoglycemia associated with disopyramide
129. pH-Dependent electrophysiological effects of quinidine and lidocaine on canine cardiac Purkinje fibers
130. Action potential, membrane currents and force of contraction in mammalian heart muscle fibers treated with quinidine
131. N-acetylprocainamide, torsades de pointes and hemodialysis
132. Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval
133. Disopyramide-induced ventricular fibrillation
134. Quinidine intoxication treated by isoproterenol (isuprel)
135. Effect of phenytoin on serum disopyramide concentrations
136. Non-fatal overdose with disopyramide
137. Clinical pharmacokinetics of quinidine
138. Procainamide-induced myasthenia-like syndrome
139. Hepatitis caused by quinidine. Study of a case and review of the literature
140. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation
141. Congestive heart failure caused by oral disopyramide
142. Anticholinergic syndrome with procainamide toxicity
143. Potentially fatal interaction between erythromycin and disopyramide
144. Resin hemoperfusion for severe N-acetylprocainamide toxicity in patients with renal failure
145. Drug purpura due to surreptitious quinidine intake
146. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus
147. Polymorphic acetylation of procainamide in man
148. Use of hemodialysis in the treatment of quinidine poisoning
149. Effects of quinidine versus procainamide on the QT interval
150. Quinidine syncope and the delayed repolarization syndromes
151. N-acetylprocainamide is a less potent inducer of T cell autoreactivity than procainamide
152. Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: intraindividual comparison in patients with sustained ventricular tachycardia
153. Clinical features and basic mechanisms of quinidine-induced arrhythmias
154. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care
155. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine
156. The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: an approach to control quinidine-induced diarrhea
157. Procainamide toxicity in a patient with acute renal failure
158. Quinidine therapy of chronic auricular fibrillation
159. Serologic changes during induction of lupus-like disease by procainamide
160. Quinidine-induced immune thrombocytopenia
161. Mechanism of reversal of toxic effects of amitriptyline on cardiac Purkinje fibers by sodium bicarbonate
162. Fatal disopyramide intoxication from suicidal/accidental overdose
163. Vascular effects of procaine amide in the dog. Predominance of the inhibitory effect on ganglionic transmission
164. Inhibition of adrenergic vasoconstriction by quinidine
165. Cerebellar ataxia due to procainamide toxicity
166. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias
167. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis
168. Procainamide-associated pancytopenia
169. The management of acute quinidine intoxication
170. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis
171. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs
172. Incidence of ventricular tachycardia or ventricular fibrillation as proarrhythmic effects during drug treatment of ventricular arrhythmia
173. Cardiogenic shock and disopyramide phosphate
174. Procainamide-induced polymorphous ventricular tachycardia
175. Quinidineinduced lupus erythematosus-like syndrome: three case reports and a review of the literature
176. Quinidine-induced syncope
177. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect
178. Plasma concentrations of quinidine, its major metabolites and dihydroquinidine in patients with torsades de pointes
179. Comparative study of a long-acting quinidine preparation and quinidine sulfate in chronic atrial fibrillation
180. Association of antibody to histone complex H2A-2B with symptomatic procainamide-induced lupus
181. Treatment of torsade de pointes with magnesium sulfate
182. Disposition kinetics of quinidine
183. Absolute quinidine bioavailability
184. Quinidine syncope: a report of successful treatment with bretylium tosylate
185. Clinical report of the use of quinidine sulfate
186. Survival after massive procainamide ingestion
187. Lethal accumulation of procainamide metabolite in severe renal insufficiency
188. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide
189. Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects
190. Antiarrhythmic activity of two quinidine metabolites in experimental reperfusion arrhythmia: relative potency and pharmacodynamic interaction with the parent drug
191. Successful treatment of quinidine and procaine amide intoxication
192. Fatal overdose with disopyramide
193. Antiguanosine antibodies: a new marker for procainamideinduced systemic lupus erythematosus
194. Value and limitations of programmed electrical stimulation of the heart in the study and treatment of tachycardias
195. Disopyramide in renal impairment
196. Quinidine intoxication treated with hemodialysis
197. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome